|
1
|
De Schepper S, Ge JZ, Crowley G, Ferreira LSS, Garceau D, Toomey CE, Sokolova D, Rueda-Carrasco J, Shin SH, Kim JS, Childs T, Lashley T, Burden JJ, Sasner M, Sala Frigerio C, Jung S, Hong S. Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease. Nat Neurosci 2023; 26:406-415. [PMID: 36747024 PMCID: PMC9991912 DOI: 10.1038/s41593-023-01257-z] [Citation(s) in RCA: 46] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 01/10/2023] [Indexed: 02/08/2023]
Abstract
Alzheimer's disease (AD) is characterized by synaptic loss, which can result from dysfunctional microglial phagocytosis and complement activation. However, what signals drive aberrant microglia-mediated engulfment of synapses in AD is unclear. Here we report that secreted phosphoprotein 1 (SPP1/osteopontin) is upregulated predominantly by perivascular macrophages and, to a lesser extent, by perivascular fibroblasts. Perivascular SPP1 is required for microglia to engulf synapses and upregulate phagocytic markers including C1qa, Grn and Ctsb in presence of amyloid-β oligomers. Absence of Spp1 expression in AD mouse models results in prevention of synaptic loss. Furthermore, single-cell RNA sequencing and putative cell-cell interaction analyses reveal that perivascular SPP1 induces microglial phagocytic states in the hippocampus of a mouse model of AD. Altogether, we suggest a functional role for SPP1 in perivascular cells-to-microglia crosstalk, whereby SPP1 modulates microglia-mediated synaptic engulfment in mouse models of AD.
Collapse
Affiliation(s)
- Sebastiaan De Schepper
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Judy Z Ge
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Gerard Crowley
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Laís S S Ferreira
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | | | - Christina E Toomey
- The Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK
- Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK
| | - Dimitra Sokolova
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Javier Rueda-Carrasco
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Sun-Hye Shin
- Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel
| | - Jung-Seok Kim
- Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel
| | - Thomas Childs
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Tammaryn Lashley
- The Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK
- Department of Neurodegenerative diseases, UCL Queen Square Institute of Neurology, London, UK
| | - Jemima J Burden
- Laboratory for Molecular Cell Biology, University College London, London, UK
| | | | - Carlo Sala Frigerio
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK
| | - Steffen Jung
- Department of Immunology and Regenerative Biology (IRB), Weizmann Institute of Science, Rehovot, Israel
| | - Soyon Hong
- UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.
| |
Collapse
|